Provide clinicians with a comprehensive menu of prenatal screening options including:1
VeriSeq NIPT Solution v2 scales according to your lab’s needs, through customized menu selection for each individual sample and versatile batch options. With a long-lasting partnership committed to your lab’s growth and continued success, together, we can shape the future of prenatal testing.
Deliver ease, accuracy, and speed to your lab with an end-to-end workflow, high accuracy, and low failure rates with VeriSeq NIPT Solution v2.
|Trisomy 21b2||Trisomy 182||Trisomy 132||RAAc2||Partial Duplications and Deletions ≥7 MB2|
Screening with VeriSeq NIPT includes dynamic fetal fraction measurement, which means lower failure rates, fewer redraws, trusted results for the clinician, and more answers delivered earlier to expecting families.2
From sample to result, all it takes is 1 technician and 2 hours of hands-on time to deliver results in about 1 day.
Rest assured that you can report timely prenatal screening results to your clinicians. The dedicated service and support team at Illumina is available for on-site assistance and phone and email communication when you need it the most.
|Sample and Library Prep||Sequencing||Data Analysis and Report Generation||Total Overall Time|
|Hands-On Time||~2 hours||~15 minutes||~2.25 hours|
|Total Time||~8 hours||~14 hours||~4 hours||~26 hours|
Actual times depend on individual lab practices and may vary; the depiction shown represents a 48-sample workflow.
Versatile batch options for 24, 48, or 96 samples per run
Customized menu selections for each sample
VeriSeq NIPT Solution v2 is a complete end-to-end in vitro diagnostic system that enables a streamlined workflow. It’s a simple, easy-to-use, automated prenatal screening solution that easily integrates into your lab’s current workflow and flexes with your lab’s growing needs. This next-generation sequencing-based, PCR-free platform provides a small footprint and less complexity for the lab.
A simple, easy-to-use, automated system seamlessly integrates into your lab’s current workflow, and flexes with your lab’s growing needs.1
This in-lab IVD NIPT assay solution delivers high accuracy with a ≥99.9% sensitivity and specificity, for results that you and your clinicians can trust.2
Results are delivered in approximately 26 hours with only 2 hours of hands-on time—clinicians and expectant families get answers faster.3
Learn more about VeriSeq NIPT Solution v2 and how it can fit into your lab.
Download the VeriSeq NIPT Solution v2 brochure.
Find the right fit for your lab with Illumina by exploring key considerations.
Learn how NIPT has become the standard for prenatal screening.
Delve into the NIPT process step by step.
The VeriSeq NIPT Solution v2 is an in vitro diagnostic test intended for use as a screening test for the detection of genome-wide fetal genetic anomalies from maternal peripheral whole blood specimens in pregnant women of at least 10 weeks gestation. VeriSeq NIPT Solution v2 uses whole-genome sequencing to detect partial duplications and deletions for all autosomes and aneuploidy status for all chromosomes. The test offers an option to request the reporting of sex chromosome aneuploidy (SCA). This product must not be used as the sole basis for diagnosis or other pregnancy management decisions.
Noninvasive prenatal testing (NIPT) based on cell-free DNA analysis from maternal blood is a screening test; it is not diagnostic. False positive and false negative results do occur. Test results must not be used as the sole basis for diagnosis. Further confirmatory testing is necessary prior to making any irreversible pregnancy decision. A negative result does not eliminate the possibility that the pregnancy has a chromosomal or sub chromosomal abnormality. This test does not screen for polyploidy (eg, triploidy), birth defects such as open neural tube defects, single gene disorders, or other conditions, such as autism. There is a small possibility that the test results might not reflect the chromosomal status of the fetus, but may instead reflect chromosomal changes in the placenta (confined placental mosaicism, CPM) or the mother that may or may not have clinical significance.